[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593805":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":25,"responsibleParty":32,"collaborators":25,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":25,"enrollmentInfo":43,"targetDuration":25,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":25,"overallStatus":52,"whyStopped":25,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":25},{"fullName":5,"class":6},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BL Predictor","EXPERIMENTAL","Parallel,non-inferiority, randomised control trial will be conducted in patients with a low-risk score stratified by BL-Predictor",[13],"Diagnostic Test: BL-Predicter",{"label":15,"type":16,"description":17,"interventionNames":18},"control","ACTIVE_COMPARATOR","St followed, if negative,by a fractioned dose DTP wirth 30 min interval between doses: 25%-25%-50% of the maximun dose",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","BL-Predicter","To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial",[9,15],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Marina Labella Alvarez MLB Bonilla Toyos","CONTACT","+34951032058","elvira.bonilla@ibima.eu",{"type":33,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100593805","in-search-of-the-correct-diagnosis-of-beta-lactam-allergy-from-the-validation-of-a-risk-stratification-tool-to-accurate-endotyping-100593805",false,"NCT07011212","In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping","Allergy","Inclusion Criteria:\n\n* signed informed consnet\n\nExclusion Criteria:\n\n* Use of immunomodulators, antihistamines and corticosteroids","ALL","14 Years",{"count":44,"type":45},332,"ESTIMATED","INTERVENTIONAL",[48],"NA","Testing a clinical decision tool (BL-Predictor)",[51],"Drug Allergy","NOT_YET_RECRUITING","2025-05-30",{"date":55,"type":56},"2025-06-08","ACTUAL",{"date":58,"type":45},"2025-07",{"date":60,"type":45},"2027-07",{"name":5,"class":6}]